KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Operating Leases (2019 - 2025)

West Pharmaceutical Services' Operating Leases history spans 7 years, with the latest figure at $118.3 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 44.62% year-over-year to $118.3 million; the TTM value through Dec 2025 reached $118.3 million, up 44.62%, while the annual FY2025 figure was $118.3 million, 44.62% up from the prior year.
  • Operating Leases for Q4 2025 was $118.3 million at West Pharmaceutical Services, up from $94.9 million in the prior quarter.
  • Across five years, Operating Leases topped out at $118.3 million in Q4 2025 and bottomed at $61.5 million in Q3 2021.
  • The 5-year median for Operating Leases is $82.7 million (2023), against an average of $84.6 million.
  • The largest annual shift saw Operating Leases soared 47.62% in 2022 before it dropped 22.34% in 2024.
  • A 5-year view of Operating Leases shows it stood at $63.0 million in 2021, then skyrocketed by 47.62% to $93.0 million in 2022, then dropped by 9.14% to $84.5 million in 2023, then fell by 3.2% to $81.8 million in 2024, then skyrocketed by 44.62% to $118.3 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Operating Leases are $118.3 million (Q4 2025), $94.9 million (Q3 2025), and $79.8 million (Q2 2025).